At the 2026 AMA Annual Meeting, delegates adopted a new policy requiring that AI tools used in clinical care integrate with physician-led teams, maintain transparent and auditable data and operate under meaningful human oversight. The resolution was not targeted at interpretation technology. But its logic applies also to it. Every requirement the AMA articulated for AI in clinical decision support, including explainability, utterance-level accountability and human-in-the-loop architecture, describes exactly what a mature AI medical interpretation platform should already be built around.

‍

Health systems evaluating AI interpretation vendors now have a policy framework from the country's largest physician organization to anchor that evaluation. The standard is not vague. It is specific, operational and gaining regulatory momentum.

‍

1. Who the AMA is and why its AI positions carry weight

The American Medical Association is the largest physician organization in the United States, representing more than 270,000 members across every specialty and practice setting. Its primary function is advocacy: shaping federal and state legislation, setting ethical standards for medical practice and publishing clinical policy that becomes reference material for accreditors, regulators and health system compliance teams. When the AMA adopts policy, it does not create law. But it creates the standard of care that law and litigation measure against.

1.1 A framework seven years in the making

The AMA has been building its health AI policy framework since 2018. The 2026 Annual Meeting resolutions are the most operationally specific it has produced. They name audit requirements, training obligations and physician-oversight structures in terms that vendor contracts and compliance reviews can be measured against. That level of specificity is new. Prior AMA AI positions read as principles. These read as requirements.

‍

1.2 The regulatory gap this closes for interpretation

For decades, AI interpretation has sat in a regulatory gap: clearly a clinical function but evaluated almost exclusively through HIPAA and language-access obligations that say nothing about audit architecture or oversight design. Title VI of the Civil Rights Act, the CLAS Standards and Section 1557 of the Affordable Care Act establish the obligation to provide interpretation. None of them specify how that interpretation must be documented, audited or overseen at the technical level. The AMA's 2026 framework closes that gap from the physician side.

‍

1.3 Why the AMA's positions carry procurement weight

AMA policy does not carry the force of regulation. What it carries is something equally consequential: the standard of care. When a health system's AI governance committee asks whether a tool was used responsibly, AMA policy is the benchmark they reach for. A vendor that cannot demonstrate alignment with the AMA's 2026 AI standards creates documentation risk for the health system.

‍

2. The governance layer health systems are now being evaluated against

Alongside the AMA's policy movement, a second governance structure emerged in May and June 2026 that compliance teams need to understand.

2.1 CHAI and its governance playbooks

The Coalition for Health AI (CHAI) is a network of more than 3,000 organizations including health systems, technology startups and patient advocacy groups that develops guidelines on responsible AI use in healthcare. In May 2026, CHAI released governance playbooks defining baseline controls across eight elements:

• Responsible AI lifecycle management. Governance from procurement through decommissioning
• Risk and impact assessments. Structured evaluation before and during deployment
• Third-party vendor management. Documentation and accountability requirements for AI vendors
• Data governance. Data use, retention and access controls
• Monitoring and performance. Ongoing evaluation of AI tool accuracy and safety
• Transparency and explainability. Requirements for how AI decisions are communicated
• Education and training. Staff readiness before AI enters clinical workflows. Discover real case example at CAN Community Health. 
• Patient privacy. Protections beyond HIPAA baseline

‍

Those playbooks were developed with input from more than 150 health AI leaders across more than 100 healthcare organizations.

‍

2.2 The Joint Commission RUAIH certification

The Joint Commission launched the Responsible Use of AI in Healthcare (RUAIH) certification on June 1, 2026, a voluntary program built directly on the CHAI playbooks. The certification does not validate individual AI products. It validates the governance structure around how a health system selects, monitors and oversees the AI tools it deploys. For health systems pursuing RUAIH certification, third-party AI vendor management is one of the eight elements they are evaluated against. That means the compliance architecture of every AI tool in the clinical environment, including interpretation, becomes part of the health system's own certification posture.

‍

2.3 The CHAI model card

CHAI also developed the model card: a standardized transparency document, sometimes called a "nutrition label" for AI procurement, that documents intended use, targeted patient populations, known risks, performance metrics and compliance accreditations. For a health system's AI governance committee evaluating an AI interpretation vendor, the model card is the starting point for due diligence. No Barrier offers CHAI model cards for health systems that need them.

‍

A health system pursuing RUAIH certification that cannot produce a CHAI model card for every AI tool in its clinical environment has a documentation gap in its third-party vendor management element. For interpretation specifically, that gap is avoidable: it requires selecting a vendor that has already prepared the documentation.

‍

‍

3. What the AMA actually resolved

As we noted at the outset, the AMA's 2026 policy was not written only with medical interpretation in mind. It addresses AI in healthcare broadly: clinical decision support, prior authorization, autonomous diagnostics, physician-led care teams. We chose to anchor this article around it because the conversation about AI governance in healthcare has also landed on interpretation. At No Barrier, medical interpretation is the entire surface we operate on and the AMA's framework, applied to that surface, produces requirements the interpretation vendor market can be held to.

The House of Delegates adopted policy across three areas at the 2026 Annual Meeting.

3.1 Evidence-based medicine integration

The AMA moved to ensure that AI clinical decision support tools reflect graded evidence hierarchies, transparent data sources and rigorous standards. 

The AMA adopted a policy stating that prior to the use of AI in the medical record, training in the use of AI is highly recommended, including the benefits and the potential risks that could exist in an AI-generated document. That policy applies directly to AI interpretation output: discharge summaries generated in a patient's language, interpreted intake notes added to the EHR and real-time encounter transcripts. If AI is producing language in the medical record, the AMA's standard now applies.

‍

3.2 AI-driven decision transparency and audit

The AMA directed advocacy for requirements that any AI tool used in clinical review be transparently audited, with reaudits triggered by material changes to the AI model, its training data or applicable clinical guidelines. For interpretation, that means audit logs at the utterance level. Not session logs. Not aggregate accuracy metrics. Individual utterances, traceable, reviewable and available if a clinical outcome is questioned.

‍

AMA CEO John Whyte put the principle directly: "AI should never function as an unaccountable black box." That sentence has a specific meaning in medical interpretation. An interpreter that cannot produce a record of what was said, in which language and at what point in the encounter, meets that definition exactly.

‍

‍

4. Why interpretation is not exempt from this standard

The February 2026 NEJM Catalyst study from Brigham and Women's Hospital, which evaluated AI interpretation alongside remote video interpretation for 23 Spanish-speaking surgical patients, found that patients did not view AI and human interpretation as competing options. They viewed each as valuable in specific contexts. AI was preferred for speed, privacy and time-sensitive scenarios. Human interpretation was preferred for emotionally complex conversations. That finding describes an architecture, not a preference. A mature AI interpretation platform integrates human oversight. It routes to it, at the right moment, in the same interface.

The AMA's 2026 policy gives that architecture a policy name: physician-led, team-based, auditable AI.

‍

‍

5. What the AMA's policy implies for interpretation vendor evaluation

The AMA did not write a vendor checklist for health systems buying interpretation technology. But its three policy resolutions, read against the clinical reality of AI interpretation, produce concrete questions that belong in any vendor evaluation today.

5.1 On AI-generated clinical notes

Where does AI-generated output land in the clinical record? The AMA adopted a policy requiring training before AI-generated content enters the medical record, covering both benefits and potential harms. Applied to interpretation, the question for any vendor is: what governance sits around discharge summaries generated in a patient's language, interpreted intake notes added to the EHR and real-time encounter transcripts? These are all AI-generated clinical content. The AMA's standard applies to each of them.

‍

5.2 On decision transparency and audit

Can the platform produce utterance-level logs? The AMA directed advocacy for requirements that AI tools used in clinical review be transparently audited, with reaudits triggered by material changes to the model, its training data or applicable clinical guidelines. For interpretation, the equivalent question is whether the platform maintains logs at the utterance level. Not session summaries. Not aggregate accuracy reports. Individual utterances, tagged to the encounter, traceable if a clinical outcome is questioned. As John Whyte stated in the June 10 AMA article: "AI should never function as an unaccountable black box."

5.3 On physician-led team integration

Is a credentialed human interpreter one tap away? The AMA adopted a policy requiring that autonomous or semiautonomous AI performing clinical functions integrate with the physician-led team and be used at the direction of the treating physician. In interpretation, that means the platform architecture needs a human interpreter available to keep the encounter and the clinical team in control.

‍

6. Where HIPAA and SOC 2 certification end and clinical compliance begins

HIPAA and SOC 2 Type II certification covers data security and privacy but compliance-literate healthcare leaders know that is not the full picture for medical interpretation. Clinical interpretation also requires human oversight for high-stakes encounters, full utterance-level audit logs and the ability to layer in protocols a health system already has in place.

‍

This is precisely what the AMA's 2026 policy codifies from the physician side. The framework is not about data protection. It is about clinical accountability: who oversaw the AI, what did it produce and can that production be reviewed.

6.1 The FQHC and safety-net exposure

For FQHCs and safety-net providers, the compliance stakes are higher, not lower. These organizations have the highest LEP patient volumes, the fewest interpreter resources per encounter and the most direct exposure to OCR enforcement under Section 1557. The AMA's framework gives their compliance officers a physician-backed standard to bring to vendor evaluations. Community Health Centers serve 52 million Americans across more than 17,000 locations. They now have two converging governance frameworks to apply: AMA policy on auditable AI and CHAI's third-party vendor management playbook.

‍

6.2 What No Barrier's compliance layer covers

No Barrier is HIPAA and SOC 2 Type II certified, with end-to-end encryption, a standard BAA and PHI deletion after 7 days. For health systems that have existing compliance frameworks, No Barrier builds compliance layers on top. That includes:

• Utterance-level audit logs Human oversight 
• CHAI model cards 
• Customized compliance frameworks 

Details on No Barrier's compliance and audit architecture are available on the FAQ page.

‍

7. The tradeoff worth naming

The AMA's policy direction is clear. Implementing it is operationally harder than signing a BAA and selecting a vendor. Health systems that want to apply the AMA's standard to AI interpretation will need to:

• Audit their current vendor's logging architecture
• Test the human escalation pathway under clinical conditions
• Map where AI-generated documentation flows into the medical record
• Confirm whether the vendor can produce a CHAI model card for governance review

‍

7.1 Why the window matters

None of that is a reason to delay. It is a reason to ask the right questions before the next contract renewal. The AMA did not set a compliance deadline. Regulators and plaintiffs' counsel often do.

‍

7.2 Where the market is heading

The vendor landscape for AI interpretation is consolidating around journey architecture and oversight. The AMA's 2026 policy adds a second vector of pressure: the physician community now has formal policy language requiring that AI in clinical care be auditable, physician-directed and transparent. CHAI's governance playbooks give health systems the procurement checklist to enforce that standard at the vendor level. AI interpretation sits inside clinical care. Both standards apply.

‍

If you are looking for an interpretation partner that understands compliance and audit at every layer, from utterance logs to CHAI model cards to customized compliance frameworks built around your existing protocols, talk to us.

‍